Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML
Authors:
- 17 August 2009
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (3) , 597-599
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Graft-versus-leukemia effects of transplantation and donor lymphocytesBlood, 2008
- Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working PartyJournal of Clinical Oncology, 2007
- Monitoring of WT1‐specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantationInternational Journal of Cancer, 2006
- Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted mannerBlood, 2005
- In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenovirusesVaccine, 2003
- Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantationBlood, 2003
- Adoptive-cell-transfer therapy for the treatment of patients with cancerNature Reviews Cancer, 2003
- WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapiesLeukemia, 2003
- HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptideBlood, 2000
- Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T LymphocytesBlood, 1999